Physician profile
Mitchell Amuda Mah'Moud
NPI 1699769257
$140,839.86
in general payments reported to CMS, 2019-2025
28 companies · $63K in 2025
The $63K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $1,282 · 2021: $493 · 2022: $876 · 2023: $12K · 2024: $41K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $26K · Honoraria: $10K · Consulting Fee: $9,163 · Travel and Lodging: $7,042 · Food and Beverage: $5,565 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,915.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,190.00 |
| Honoraria | $10,170.00 |
| Consulting Fee | $9,162.50 |
| Travel and Lodging | $7,041.60 |
| Food and Beverage | $5,564.99 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $52,855.34 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $36,330.42 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $34,500.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $12,342.98 | 2019 | |
| Mirum Pharmaceuticals, INC. | $1,625.00 | 2025 | Ctexli |
| Abbvie INC. | $1,285.54 | 2021-2025 | |
| Pfizer INC. | $478.78 | 2021-2025 | |
| Gilead Sciences, INC. | $361.71 | 2021-2025 | Livdelzi |
| Ferring Pharmaceuticals INC. | $188.68 | 2022-2023 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.05 | 2021-2024 | Xifaxan, Trulance, Plenvu |
| Novo Nordisk INC | $100.88 | 2023 | |
| Celgene Corporation | $93.68 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $85.73 | 2022-2023 | Dupixent |
| Aimmune Therapeutics, INC. | $81.64 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $63.25 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $61.31 | 2020-2021 | |
| Genzyme Corporation | $50.00 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $40.71 | 2021-2023 | Dificid |
| Ardelyx, INC. | $31.15 | 2022-2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $29.77 | 2023-2025 | Entyvio |
| Orphalan INC | $20.62 | 2024 | Cuvrior |
| Ironwood Pharmaceuticals, INC | $19.93 | 2023 | Linzess |
| Janssen Biotech, INC. | $18.49 | 2025 | Simponi Aria, Stelara, Simponi |
| Qol Medical, LLC | $16.76 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Mah'Moud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.